Hanmi Pharmaceutical's board replaces CEO Park Jae-hyun and four directors, appointing HB Investment's Hwang Sang-yeon as new chief candidate amid ongoing management dispute between major shareholders and professional managers over company direction and founding principles.
#YonhapInfomax #HanmiPharmaceutical #CeoReplacement #HwangSangyeon #ManagementDispute #BoardRestructuring #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=109619
Hanmi Pharmaceutical Replaces CEO Park Jae-hyun, Names Hwang Sang-yeon as New Chief Candidate
Hanmi Pharmaceutical's board replaces CEO Park Jae-hyun and four directors, appointing HB Investment's Hwang Sang-yeon as new chief candidate amid ongoing management dispute between major shareholders and professional managers over company direction and founding principles.
Yonhap Infomax
Korea Zinc Board Restructured with 15-4 Majority for Choi Yun-bum (Comprehensive)
Korea Zinc board restructures with 15-4 majority for Chairman Choi Yun-bum, as Youngpoong and MBK Partners gain representation amid voting rights restrictions and cumulative voting.
Yonhap Infomax
Shareholder Meeting Season Without Activist Funds - Key Points to Watch This Year
Shareholder meetings in South Korea see shift from activist fund pressure to focus on board restructuring and shareholder returns, with major companies like Samsung and Hyundai making significant changes.
Yonhap Infomax
Hanmi Science Appoints Chairwoman Song Young-sook as New CEO, Ending Management Dispute
Hanmi Science appoints Chairwoman Song Young-sook as new CEO, signaling end to year-long management dispute and focus on organizational stability and business normalization
Yonhap Infomax